Q2 2024 · 13F-HR
BML Capital Management, LLCholdings as filed
Filed 2024-08-07 · accession 0001754960-24-000403
$140.1M
Reported value
28
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 46436E718 | SGOV | ISHARES TR | $27.2M | 19.4% | 270,000 | Common | NONE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $21.1M | 15.1% | 6,375,621 | Common | NONE |
| 78468R663 | BIL | SPDR SER TR | $18.4M | 13.1% | 200,000 | Common | NONE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $14.3M | 10.2% | 12,988,134 | Common | NONE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $13.5M | 9.62% | 1,966,000 | Common | NONE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $7.7M | 5.48% | 466,047 | Common | NONE |
| 75974E103 | — | RENEO PHARMACEUTICALS INC | $4.0M | 2.88% | 2,672,194 | Common | NONE |
| 45783C200 | TIL | INSTIL BIO INC | $4.0M | 2.87% | 391,103 | Common | NONE |
| 974155103 | WING | WINGSTOP INC | $3.6M | 2.56% | 714 | PUT | NONE |
| 68403P203 | ORMP | ORAMED PHARMACEUTICALS INC | $3.5M | 2.47% | 1,349,038 | Common | NONE |
| 207523101 | — | CONNECT BIOPHARMA HLDGS LTD | $3.1M | 2.22% | 2,043,248 | Common | NONE |
| 04746L104 | — | ATHIRA PHARMA INC | $2.4M | 1.70% | 900,000 | Common | NONE |
| 921659108 | VNDA | VANDA PHARMACEUTICALS INC | $2.3M | 1.61% | 398,280 | Common | NONE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $2.1M | 1.51% | 1,309,397 | Common | NONE |
| 046484309 | ASTC | ASTROTECH CORP | $2.0M | 1.40% | 220,410 | Common | NONE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $1.5M | 1.04% | 1,102,895 | Common | NONE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $1.4M | 1.01% | 421,749 | Common | NONE |
| 92511W108 | — | VERRICA PHARMACEUTICALS INC | $1.3M | 0.94% | 180,000 | Common | NONE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $1.1M | 0.79% | 63,916 | Common | NONE |
| 128058302 | LSTA | LISATA THERAPEUTICS INC | $987,801 | 0.70% | 284,669 | Common | NONE |
| 45175G108 | — | IKENA ONCOLOGY INC | $965,438 | 0.69% | 585,114 | Common | NONE |
| 34962G109 | TOCAEUR | FORTE BIOSCIENCES INC | $946,034 | 0.68% | 1,761,702 | Common | NONE |
| 38942Q202 | CALC | CALCIMEDICA INC | $635,279 | 0.45% | 160,424 | Common | NONE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $522,000 | 0.37% | 150,000 | Common | NONE |
| 00449L102 | 698 | ACHILLES THERAPEUTICS PLC | $509,517 | 0.36% | 625,174 | Common | NONE |
| 65343E108 | NXTCEUR | NEXTCURE INC | $439,579 | 0.31% | 276,465 | Common | NONE |
| 019818103 | — | ALLOVIR INC | $436,212 | 0.31% | 603,086 | Common | NONE |
| 87424L207 | TLIS | TALIS BIOMEDICAL CORP | $370,231 | 0.26% | 42,743 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.